CEPI, the Coalition for Epidemic Preparedness Innovations, will provide seed funding of up to $4.8 million to Intravacc BV to advance the development of a broadly protective betacoronavirus vaccine candidate, which can be delivered intranasally.
Hanall Biopharma Co. Ltd. has clarified that the new FcRn inhibitor IMVT-1402, unveiled by its licensed partner Immunovant Inc. as a new development program for autoimmune diseases, is a compound discovered and developed by Hanall, HL-161ANS.
Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines.
Tumor mutational burden (TMB), a biomarker used to assess whether a patient will respond to immunotherapy, needs to be recalculated in order to be useful for patients of Asian or African descent. Scientists at the Dana-Farber Cancer Institute found a significant bias in the estimated TMB values affecting these populations and adjusted them for those patients.
The Nobel Prize in Physiology or Medicine 2022 was awarded to Svante Pääbo today "for his discoveries concerning the genomes of extinct hominins and human evolution." Pääbo, who is currently the director of the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, and his colleagues overcame extreme technical challenges to sequence the DNA of ancient hominids – because after tens of thousands of years, there is no such thing as aging well for DNA.
A research consortium comprised of XL-protein GmbH, Wacker Chemie AG and Ludwig-Maximilians-Universität München (LMU) will develop a novel long-acting immunosuppressive anti-CD40 antibody fragment for the selective suppression of organ rejection, in particular in the area of cardiac xenotransplantation.
Cancer-associated fibroblasts (CAF) expressing the LRRC15 protein (leucine-rich repeat-containing protein 15) could be responsible for the suppression of antitumor immunity, according to a study using mouse models of pancreatic cancer. Scientists from Roche Holding AG subsidiary Genentech Inc. demonstrated in vivo that TGF-β type 2 receptor signaling in healthy universal fibroblasts produces cancer-associated LRRC15+ myofibroblasts.
Almirall SA and Simcere Pharmaceutical Group Ltd. have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM-0278.
Immunovant Inc. has announced a next-generation anti-FcRn, IMVT-1402, for autoimmune diseases. In animal studies, IMVT-1402 has shown deep IgG lowering, similar to the company's lead asset batoclimab, with no or minimal impact on albumin and low-density lipoprotein (LDL).
RSS
